daily oral glp-1 receptor agonist orforglipron for adults with obesity Oral GLP-1 Receptor Agonist for
Description
A.et al (2016b)
This highlights that traditional approaches to curbing the prevalence of overweight and obesity have had limited success
What the Findings Could Change for Patients with Obesity and AFib The results provide a paradigm shift in how clinicians might approach treatment of patients with Afib, particularly those with obesity and persistent AFib, for catheter ablation
1 Similarly, 72 weeks treatment with tirzepatide (5, 10 or 15 mg) produced weight loss of 15-21% in the SURMOUNT-1 trial
NCD Risk Factor Collaboration (NCD-RisC)
